Clinical Trials Directory

Trials / Sponsors / Qurient Co., Ltd.

Qurient Co., Ltd.

Industry · 10 registered clinical trials — 2 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease
Chronic Graft-Versus-Host Disease
Phase 12025-12-23
Active Not RecruitingOral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer
Phase 1 / Phase 22023-01-12
RecruitingHighly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Advanced Cancer, Metastatic Cancer
Phase 1 / Phase 22022-08-30
TerminatedA Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec
COVID-19 Virus Infection
Phase 22021-07-29
CompletedOral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
Solid Tumor, Advanced Cancer, Metastatic Cancer
Phase 12020-11-18
CompletedA Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multipl
Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB
Phase 22018-07-23
CompletedSafety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients
Atopic Dermatitis
Phase 22018-06-21
CompletedA Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Nor
Healthy Volunteers
Phase 12016-08-01
CompletedA Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Norma
Healthy Volunteers
Phase 12015-08-01
CompletedSafety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
Moderate to Severe Atopic Dermatitis
Phase 22015-04-01